A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
← catalyst calendarNCT06143956 · readout ≤ 407 d
Sponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Double · Screening
Enrollment
1,481estimated
Sites
54
Countries
Argentina, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-11-17 | actual | When the study began enrolling |
| Primary completion | Sep 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Feb 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2023-11-22 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Obesity
- Overweight
Interventions
- Drug: LY3305677
- Drug: LY3841136 — also filed as Eloralintide
- Drug: Tirzepatide — also filed as LY3298176
- Drug: LY3549492
- Drug: LY3532226 — also filed as Macupatide
- Drug: Placebo
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFNumber of Participants Allocated to Each ISA
measured Baseline to Week 6
Posted documents
hosted by the registry — we link, never re-serveStudy Protocolposted 2025-12-12 · 3.1 MB · Prot_000.pdf
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed